A post-spin, AAA-rated “defensive growth machine” pivoting into an Oncology–Cardiovascular double engine—yet still shadowed by Stelara’s patent cliff, a PFA slugfest, and talc’s legal overhang.
Overview
Johnson & Johnson has re-emerged from the 2023 Kenvue consumer spin as a streamlined, innovation-centric healthcare leader focused on Innovative Medicine and MedTech. In FY2025—framed by management as a “catapult year”—JNJ produced $94.2B in sales and 5.3% operational growth despite the loss of exclusivity headwind from Stelara. Innovative Medicine generated $60.4B (with oncology as the centerpiece), while MedTech delivered $33.8B supported by electrophysiology leadership and the high-growth additions of Abiomed and Shockwave. The portfolio is unusually diversified and resilient, anchored by 28 billion-dollar platforms; Darzalex is the crown jewel at >$14B in 2025. With $19.7B in free cash flow and $14.7B of R&D investment, JNJ is positioned as a premium-valued “defensive growth” compounder, balancing durable cash generation with higher-stakes execution in PFA, robotics, and litigation resolution.